Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03189030 · ClinicalTrials.gov registry record · Phase 1
Study of Personalized Immunotherapy in Adults With Metastatic Colorectal Cancer
A Phase 1 study, sponsored by Aduro Biotech.
- Terminated
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT03189030: Clinical Trial Phase 1 study, sponsored by Aduro Biotech.
NCT03189030 is a Phase 1 study that was terminated before completion, run by Aduro Biotech. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03189030, a Phase 1 study, was terminated before completion, sponsored by Aduro Biotech.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This study will evaluate the safety and tolerability of a personalized live, attenuated, double-deleted Listeria monocytogenes (pLADD) treatment in adults with metastatic colorectal cancer.
Interventions
- BIOLOGICAL pLADD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2017-05-02 |
| Est. Completion | 2020-09-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03189030
The ClinicalTrials.gov registry entry for NCT03189030 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aduro Biotech, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pLADD is the first listed.
NCT03189030 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03189030 about?
NCT03189030 is a clinical study titled "Study of Personalized Immunotherapy in Adults With Metastatic Colorectal Cancer". This study will evaluate the safety and tolerability of a personalized live, attenuated, double-deleted Listeria monocytogenes (pLADD) treatment in adults with metastatic colorectal cancer.
What is the current status of trial NCT03189030?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2017-05-02. Estimated completion is 2020-09-02.
What interventions are being tested in trial NCT03189030?
The interventions under investigation include: pLADD (BIOLOGICAL).
Who is sponsoring clinical trial NCT03189030?
This trial is sponsored by Aduro Biotech, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.